Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Wednesday the availability of Atomoxetine Capsules, USP in the US market.
In addition, the company's Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size. Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD), including psychological, social, and other treatments. It may help to increase the ability to pay attention, concentrate, stay focused and stop fidgeting.
The company said the US Food and Drug Administration (USFDA) approved Atomoxetine Capsules, USP, is the therapeutic equivalent generic version of Strattera (atomoxetine) Capsules. Straterra is a registered trademark of Eli Lilly and Company.
For the most recent 12 months ending in August 2018, the Strattera brand and generic had US sales of about USD304m MAT, according to IMS Health.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling